Equivalent of Form PTO/SB/08a (2-09) Substitute for form 1449/PTO Complete if Known Application Number 10/553,703 INFORMATION DISCLOSURE Filing Date April 16, 2004 First Named Inventor FIKES, John D. STATEMENT BY APPLICANT Art Unit 1642 (Use as many sheets as necessary) Examiner Name DAVIS, Minh Tam B Sheet 1 of 1 Attorney Docket Number 2060.0150007/EKS/PAC

			U.S. PATENT DO	OCUMENTS		
Examiner Initials	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentes or Applicant of Cited Document	Pages, Columns, Lines,	
Initials'	140.	Number-Kind Code <sup>2 (IrKnown)</sup>	WIM-DD-1111	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appea	
_	US1	5,686,068	11/11/1997	Melief et al.		
	US2	5,846,827	12/08/1998	Celis et al.		
	US3	6,063,900	05/16/2000	Melief et al.		
	US4	6,075,122	06/13/2000	Cheever et al.		
	US5	2002/0119127 A1	08/29/2002	Sette et al.		
	US6	2003/0224036 A1	12/04/2003	Fikes et al.		
	US7	2007/0098776 A1	07/10/2006	Fikes et al.		
	US8	2008/0279924 A1	10/29/2007	Fikes et al.		
		-				
			<del> </del>			
		†				
		1			1	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document  Country Code' Number' Kind Code' (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or			
					Relevant Figures Appear	Te		
	FP1	WO 94/020127 A1	09/15/1994	Cytel Corporation				
	FP2	WO 95/04817 A1	02/16/1995	Cytel Corporation	1			
	FP3	WO 95/22561 A2	08/24/1995	University of Virginia Patent Foundation				
	FP4	WO 96/18409 A1	06/20/1996	The Scripps Research Institute				
	FP5	WO 98/33888 A1	08/06/1998	Epimmune, Inc.				
	FP6	WO 01/41741 A1	06/14/2001	Epimmune, Inc.		_		
	FP7	WO 02/10379 A2	02/07/2002	Aventis Pasteur Limited; Therion Biologics; National Cancer Institute		Γ		

981524v1

Examiner		Date	
Signature	/Minh Tam Davis/ (08/25/2009)	Considered	

\*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 809, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \*Enter Office that issued the document, by the two-tetter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. I kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Compare, including generating, preparing, and southering are completed application from the 1905 FO. This was very operating point and information of the compared from the amount of third poor program to complete this form and/or suggestions for reducing this burder, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

					Equivalent of Form FTO/Sb/000 (2-0)		
Substitute for fo	orm 1449/PT	О		Complete if Known			
			Application Number	10/553,703			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			LOSURE	Filing Date	April 16, 2004		
			PLICANT	First Named Inventor	FIKES, John D.		
a	Ise as many	sheets o	is necessary)	Art Unit	1642		
				Examiner Name	DAVIS, Minh Tam B.		
Sheet	1	of	3	Attorney Docket Number	2060.0150007/EKS/PAC		

Examiner	Cite No.	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	
Initials*	Cite No.	of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL1	Alters, S.E., et al., "Immunotherapy of Cancer: Generation of CEA Specific CTL Using CEA Peptide Pulsed Dendritic Cells," Dendritic Cells in Fund. and Clin. Immunol. 3:519-524, Plenum Press, United States (1997)	
	NPL2	Bakker, A.B.H., et al., "Analogues of CTL Epitopes with Improved MHC Class-I Binding Capacity Elicit Anti-Melanoma CTL Recognizing the Wild-Type Epitope," Int. J. Cancer 70:302-309, Wiley-Liss, United States (1997)	
	NPL3	Bremers, A.J.A., et al., "The Use of Epstein-Barr Virus-Transformed B Lymphocyte Cell Lines in a Peptide-Reconstitution Assay: Identification of CEA-Related HLA-A*0301-Restricted Potential Cytotoxic T-Lymphocyte Epitopes," J. Immunother. 18:77-85, Lippincott-Raven, United States (1995)	
		Celis, E., et al., "Epitope selection and development of peptide based vaccines to treat cancer," Semin. Cancer Biol. 6:329-336, Academic Press, England (1995)	
	NPL5	Chikamatsu, K., et al., "Generation of Anti-p53 Cytonoxic T Lymphocytes from Human Peripheral Blood Using Autologous Dendritic Cells," Clin. Cancer Res. 5:1281-1288, the American Association for Cancer Research, United States (1999)	
NPL6 Human Cytotoxic		Cox, A.L., et al., "Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines," Science 264:716-719, American Association for the Advancement of Science, United States (1994)	
	NPL7	DeLeo, A.B. "p53-Based Immunotherapy of Cancer," Crit. Rev. Immunol. 18:29-35, Begell House, Inc., United States (1998)	
		Gambacorti-Passerini, C., et al., "Mapping of HLA Class I Binding Motifs in Forty-four Fusion Proteins Involved in Human Cancers," Clin. Cancer Res. 3:675-683, The Association, United States (1997)	
	Greenberg, P.D., "Adoptive T Cell Therapy of Tumors: Mechanisms Operative in NPL9 Recognition and Elimination of Tumor Cells," Adv. Immunol. 49:281-355, Acader Press, United States (1991)		
	NPL10	Ioannides, C.G., et al., "T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy," Mol. Carcinog. 6:77-82, Wiley-Liss, United States (1992)	

Examiner Signature	/Minh Tam Davis/ (08/25/2009)	Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and							

<sup>&</sup>quot;EXAMINES: initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation in not in conformance and not considered, include copy of this form with next communication to applicant is to place a theck mark here it English in anguage Translation is statched. 'Applicant's unique citation designation number (controls). 'Applicant is to place a theck mark here it English in anguage Translation is statched. 'Applicant's to place a theck mark here it English in anguage Translation is statched. 'But the control is statched in the control is statched. 'But the control is statched.' But the control is statched. 'But the control is statched.' But the control is statched. 'But the control is statched.' But the control is statched. 'But the control is statched.' But the control is statched. 'But the control is statched.' But the control is statched.' But

Substitute for	form 1449/PT	0		Complete if Known		
				Application Number	10/553,703	
INFORM	I NOITAN	DISC	LOSURE	Filing Date	April 16, 2004	
STATE	STATEMENT BY APPLICANT			First Named Inventor	FIKES, John D.	
0.71.	(Use as many.			Art Unit	1642	
				Examiner Name	DAVIS, Minh Tam B.	
Sheet	2	of	3	Attorney Docket Number	2060.0150007/EKS/PAC	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL11	Kawashima, I., et al., "Identification of HLA-A3-restricted Cytotoxic T Lymphocyte Epitopes from Carcinoembryonic Antigen and HER-2/neu by Primary in Vitro Immunization with Peptide-pulsed Dendritic Cells," Cancer Res. 59:431-435, American Association for Cancer Research, United States (1999)	
	NPL12	Keogh, E., et al., "Identification of New Epitopes from Four Different Tumor- Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A*0201-Binding Affinity," J. Immunol. 167:787-796, American Association of Immunologists, United States (2001)	
	NPL13	Lustgarten, J., et al., "Identification of Her-2/Neu CTL Epitopes Using Double Transgenic Mice Expressing HLA-A.2.1 and Human CD.8," Hum. Immunol. 52:109- 118, Elsevier Science, United States (1997)	
	NPL14	Mateo, L., et al., "An HLA-A2 Polyepitope Vaccine for Melanoma Immunotherapy," J. Immunol. 163:4058-4063, American Association of Immunologists, United States (1999)	
	NPL15	Melief, C.J.M., and Kast, W.M., "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication in General," Cancer Surv. 13:81-99, Cold Spring Harbor Press, United States (1992)	
	NPL16	Parkhurst, M.R., et al., "Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues," J. Immunol. 157:2539-2548, American Association of Immunologists, United States (1996)	
	NPL17	Petersen, T.R., et al., "Identification and Design of p53-Derived HLA-A2-Binding Peptides with Increased CTL Immunogenicity," Scand. J. Immunol. 53:357-364, Blackwell Science Ltd., England (2001)	
	NPL18	Ras, E., et al., "Identification of Potential HLA-A*0201 Restricted CTL Epitopes Derived from the Epithelial Cell Adhesion Molecule (Ep-CAM) and the Carcinoembryonic Antigen (CEA)," Hum. Immunol. 53:81-89, Elsevier Science, United States (1997)	
	NPL19	Rivoltini, L., et al., "Binding and Presentation of Peptides Derived from Melanoma Antigens MART-1 and Glycoprotein-100 by HLA-A2 Subtypes. Implications for Peptide-Based Immunotherapy," J. Immunol. 156:3882-3891, American Association of Immunologists, United States (1996)	
	NPL20	Toes, R.E.M., et al., "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion," Proc. Natl. Acad. Sci. USA 94:14660-14665, National Academy of Sciences, United States (1997)	

Examiner Signature	/Minh Tam Davis/ (08/25/2009)	Date Considered					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and							

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw the through citation if not in conformance and not considered, include copy of this form with event communication to applicant is unique citation designation number (costonal). Applicant is to place a check match here in English inauquee Transistion tatzehed.

\*\*Applicant's unique citation designation number (costonal). Applicant is to place a check match here in English in unique parameterism tracted.

\*\*LENTO to processes an application Confidentiality is gowered by 39 US.C. 122 and 37 CRF 11.4 This collection is estimated to before to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to completed in application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent in Christ Individual case. Any comments on the ADD To Commissioner for Patients, P.O. Box 1439, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1439, Alexandria, VA 22313-1450.

Equipolant of Form DTO/SD/09b /2 06

Substitute for	form 1449/PT0	)	-	Complete if Known			
				Application Number	10/553,703		
INFORM	IATION D	DISC	LOSURE	Filing Date	April 16, 2004		
STATEMENT BY APPLICANT				First Named Inventor	FIKES, John D.		
	(Use as many s			Art Unit	1642		
				Examiner Name	DAVIS, Minh Tam B.		
Sheet	3	of	3	Attorney Docket Number	2060.0150007/EKS/PAC		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>		
	NPL21	Tsang, K.Y., et al., "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine," J. Natl. Cancer Inst. 87-982-990, Oxford University Press, United States (1995)			
	NPL22	Valmori, D., et al., "Analysis of MAGE-3-specific Cytolytic T Lymphocytes in Human Leukocyte Antigen-A2 Melanoma Patients," Cancer Res. 57:735-741, American Association for Cancer Research, United States (1987)			
	NPL23	International Search Report for International Application No. PCT/US04/11895, mailed June 27, 2008, ISA/US, United States			
	NPL24	Supplementary European Search Report for European Application No. 04 75 9962, mailed May 6, 2009, European Patent Office, Germany			
	NPL25	Examiner's First Report for Australian Application No. 2004232971, mailed December 16, 2008, Australian Patent Office, Australia			
			Г		

981531v1

Examiner		Date	
Signature	/Minh Tam Davis/ (08/25/2009)	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with exet communication to applicant is to place a check match there is English imagines prematerion is statched. "Applicant is unique citation designation number (piptional)." Applicant is to place a check match there is English imagines prematerion is statched. "Applicant is unique citation designation number (piptional)." Applicant is to place a check match there is English imagines in the public which is to file (and by the USFTO in process) an application Conformativity is operanted by 39 US.S. 122 and 37 CFT.11.1. This collection is estimated to both one bourse to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing the tomorphism, should be sent in Celler Information Officer, U.S. Patent and Taxionark Office, P.O. Box 1489, Okazandia, VX 2313-1460. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1489, Alexandria, VX 22313-1460.